TAVR for Asymptomatic Severe Aortic Stenosis (AS): Results of the EARLY TAVR Trial

The EARLY TAVR trial is the first randomized, controlled trial studying the role of early intervention with TAVR as compared to clinical surveillance in asymptomatic severe AS disease management. Results were presented at TCT 2024 and published in The New England Journal of Medicine.

In this trial, early intervention with TAVR was superior to clinical surveillance for the primary endpoint of death, stroke, or unplanned cardiovascular hospitalization* (26.8% vs 45.3%).

Download

*Includes any unplanned cardiovascular hospitalization and any aortic valve intervention or reintervention within 6 months.

Watch the EARLY TAVR trial results presented at TCT 2024 by Dr. Philippe Genereux:

Video

TAVR for asymptomatic severe aortic stenosis with Philippe Genereux, MD

Watch
Presentation

Presentation slides from Philippe Genereux, MD

Download

Listen to expert perspectives on the treatment of patients living with severe AS:

Video

Traditional thinking and the current guidelines for severe AS management with Allan Schwartz, MD

Watch
Video

A surgeon's perspective on the medical and societal impact of waiting for symptoms with Mark J. Russo, MD

Watch

Stay connected

Be the first to receive the latest news in transcatheter heart valves, including event announcements.

References:   1. Généreux P, Schwartz A, Oldemeyer JB, et al. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N Engl J Med. 2025;392(3):217-227.